Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.
Description
Deeplink Medical has centered its offerings around the MIRIO platform, which is designed to cater to the varying use cases and requirements of stakeholders engaged in medical imaging within oncology, both in clinical settings and routine practice. Our services encompass three distinct yet interconnected solutions: MIRIO, which tracks evaluations of solid tumors and monitors the therapeutic responses of oncology patients; a streamlined patient pathway that bridges hospital facilities with private medical practices; and an Imaging CRO dedicated to the oversight of imaging data in oncological clinical trials. The development of our innovative solutions is bolstered by a scientific board, ensuring a robust foundation for our offerings. Additionally, our collaborative workflow platform organizes imaging data and radiological assessments for patients with solid tumors, facilitating real-time data structuration in accordance with RECIST 1.1 and iRECIST guidelines right from the moment the data is generated at investigation sites. This enables immediate evaluation of treatment responses based on established international standards, ultimately enhancing the quality and efficiency of patient care in oncology. By integrating these services, we aim to provide a comprehensive approach that supports healthcare professionals in delivering optimal treatment outcomes.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Gritstone bio
Founded
2015
Country
United States
Website
gritstonebio.com/scientific-platform/
Vendor Details
Company Name
DEEPLINK MEDICAL
Country
France
Website
www.deeplink-medical.com/en/medical-imaging-in-oncology/
Product Features
Product Features
Medical Imaging
Automated Routing
No
Comparison View
No
Compliance Management
No
Data Import / Export
No
Diagnostic Reporting
No
Image Analytics
No
Treatment Planning
No
Workflow Management
No